MSD

News

MSD, Eisai abandon combination trial in liver cancer

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

News

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.

News

MSD advances on a broad front with TL1A drug tulisokibart

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

News

Verona shareholders back $10bn MSD takeover

MSD has moved a step closer to completing its acquisition of Verona Pharma, after a vote in favour of the transaction by the UK firm's shareholders.

News

MSD's $345m alliance with Variational, and other AI news

MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.

News

FDA clears subcutaneous Keytruda in a boost to MSD

MSD's Keytruda will soon be available as a subcutaneous injection, improving convenience for patients and defending it from a looming patent loss.

MSD, Eisai abandon combination trial in liver cancer

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

MSD advances on a broad front with TL1A drug tulisokibart

Verona shareholders back $10bn MSD takeover

MSD's $345m alliance with Variational, and other AI news

FDA clears subcutaneous Keytruda in a boost to MSD

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

MSD

Editor's Picks